



## Immune Responses to COVID-19 Vaccines

Guest Editor:

**Dr. Federico De Marco**

Department of RDAT, the Regina  
Elena National Cancer Institute  
IRCCS, Via Elio Chianesi 53, 00144  
Rome, Italy

Deadline for manuscript  
submissions:

**closed (31 January 2023)**

### Message from the Guest Editor

Dear Colleagues,

Special Issue includes but is not restricted to the following:

- Use, efficacy, and safety of COVID-19 vaccines in frail persons such as, but not limited to, patients with cardiopulmonary chronic diseases, COPD, Diabetes, chronic renal failure, renal transplant carriers, and oncological/onco-hematological patients; in extreme ages (elderly/newborn), in pregnancy, in patients with chronic viral infections (HIV, HBV, or HCV), primary or secondary immune depression, or suffering from immune, allergic, or autoimmune diseases, either in treatment with immune modifying drugs or not
- Impact of COVID-19 vaccines in hospitalized/institutionalized persons and personnel and in special communities
- Off label use of COVID-19 vaccines: heterologous or mixed prime-boost schedules, extended prime to boost interval
- Interaction between COVID-19 vaccines and other vaccinations in newborns, in frail newborns (to an HIV/HBV/HCV-positive mother), in elderly, in multiple exposed frail patients
- Use and development of COVID-19 vaccines in medium–low-income countries or communities
- Next generation, new formulation, and new conception of COVID-19 vaccines.





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)